Imaging of Brain Amyloid Plaques in the Aging Population

Alzheimer's Disease Clinical Trial

Official title: Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia

Status Enrolling by invitation

Clinical Trial Summary

This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.

Clinical Trial Description

Identification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. We plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. Long term followup of these subjects will allow us to understand the predictive ability of this new test. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Aphasia, Primary Progressive
• Dementia
• Dementia With Lewy Bodies
• Dementia, Vascular
• Frontotemporal Dementia
• Lewy Body Disease
• Pick Disease of the Brain
• Vascular Dementia

• NCT number: NCT00950430
• Study type: Interventional
• Source: Mayo Clinic
• Status: Enrolling by invitation
• Phase: Phase 4
• Start date: April 2008
• Completion date: June 2024